Walgreens says taking time to evaluate all aspects of Alliance Boots transaction Says company making significant progress evaluating proposed transaction with Alliance Boots. Says will accelerate optimization efforts to lower expenses. Says expects rate of generic drug introductions to increase in Q4, says should not be a drag on margins in the quarter. Sees front-end margin continuing to improve over the long-term. Sees interest expense of approximately $35M in Q4. Sees Q4 GAAP tax rate 36%. Comments made on the Q3 earnings conference call.